Skip to content
Review Open access

Moving beyond the neutral-Darwinian dichotomy to inform precision oncology.

Jul 2026 · npj Precision Oncology · 0 citations
Medicine

TL;DR

It is argued that tumour evolution is not a binary state, but a dynamic continuum shaped by genetic and non-genetic heterogeneity, spatial constraints, microenvironmental pressures and therapeutic bottlenecks, which will align these models with therapeutic decision-making in precision oncology.

Abstract

Current methods for distinguishing neutral from selection-driven tumour evolution rely on assumptions frequently violated in clinical samples. We argue that tumour evolution is not a binary state, but a dynamic continuum shaped by genetic and non-genetic heterogeneity, spatial constraints, microenvironmental pressures and therapeutic bottlenecks. Refining evolutionary inference through integrative, longitudinal and spatially resolved analyses will be essential to align these models with therapeutic decision-making in precision oncology.

Read PDF

Similar papers

Review Open access Sep 2026

Evolutionary genomics, tumor dynamics, and mathematical modeling of cancer progression: Implications for precision oncology.

This review synthesizes current knowledge on clonal dynamics, intratumor heterogeneity (ITH), and the mathematical tools used to model cancer progression, with direct implications for the design of precision oncology strategies.

Wei Li, Xiao-Tong Wang · 0 citations
Review Sep 2026

A guide to understanding tumour evolution through the lens of population genetics.

It is argued that population genetics provides the mathematical framework needed to extract evolutionary dynamics from cancer genomes and it is shown how models of mutation, selection and drift transform allele frequencies from descriptive measurements into quantitative estimates of clonal fitness and evolutionary timi...

G. Caravagna, Trevor A. Graham, A. Sottoriva · 1 citation
Review Open access Sep 2026

Decoding hidden inceptions: The evolution from indolent to aggressive cancers.

It is proposed that tumor indolence is an actively maintained condition of restrained malignant potential, sustained by a multilayer restraint architecture encompassing lineage and epigenetic barriers, epithelial cell competition, immune containment, stromal organization, and vascular and metabolic limitations.

Xin-Pu Tang, Tian-Jian Lu, Mengyao Wang et al. · 0 citations
Open access Aug 2026

Rapid resolution of variants of uncertain significance (VUS). A complementary role for zebrafish in the era of multi-million-dollar therapies

Rapid in vivo zebrafish assays can help to resolve variant pathogenicity within weeks, providing organism-level evidence that informs treatment decisions, prevents unnecessary interventions, and strengthens precision medicine.

J. Giacomotto · 0 citations
Review Aug 2026

Charting intratumor heterogeneity from bench to bedside

The current understanding of heterogeneity and evolution is synthesized and it is discussed how these insights can inform the development of evolution-aware diagnostic and therapeutic strategies.

J. Wan, N. Mcgranahan, C. Swanton · 0 citations
Review Open access Sep 2026

Heterogeneity in cancer: molecular mechanisms and therapeutic strategies

The Holistic Integrative Tumor Ecosystem Theory (HITET) is proposed, a five-dimensional framework connecting these scales through functional interfaces that synthesizes how genetic alterations, cellular plasticity, metabolic programs, immune and stromal interactions, spatial gradients, organ-specific environments, micr...

Yong-Lin He, Liang Niu, Yan-Ming Ren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.